14 results about "Carbohydrate antigen" patented technology

The present invention relates to a cancer vaccine conjugate comprising a CRM197 carrier protein and an immunogenic peptide covalently linked to the residues C186 and 0201 of the CRM197 carrier by means of a linker. Suitable immunogenic peptides include glycopeptides, such as glycopeptides comprising a tumor associated carbohydrate antigen (TACA) (e.g., GalNAc, Galb (1, 3) GalNAc or Neu5Ac alpha (2-6) GalNAc). Cancer vaccine conjugates, methods of producing and uses thereof are provided.

The invention relates to the technical field of immunosensors, in particular to a Gd MOF composite material, an immunosensor and a preparation method and application of the immunosensor. The preparation method of the Gd MOF composite material comprises the following steps: dissolving polyether F127 in a mixed solvent, then adding gadolinium (Gd) salt and 5-aminoisophthalic acid (5-AIPA), and carrying out a first heating reaction to obtain Gd MOF; and dispersing the Gd MOF in a copper salt solution, and carrying out a second heating reaction to obtain the Gd MOF composite material. The invention also provides the double-ligand Gd MOF composite material prepared by adopting the method, an antibody-combined illuminant, an immunosensor and a preparation method of the double-ligand Gd MOF composite material. The invention provides a novel MOF material which is used for an ECL sensing system, and efficient detection of carbohydrate antigen 19-9 (CA19-9) is achieved.

The invention relates to the technical field of medical diagnosis and artificial intelligence aided decision making, and discloses a pancreatic cancer early screening method for people with new diabetes mellitus based on MUC2 pancreatic cancer cell exosome ACOT7. Detecting expression levels of three biomarkers, namely ACOT7 protein, MUC2 protein and serum carbohydrate antigen CA19-9, derived from pancreatic cancer cell exosomes in blood, inputting a pancreatic cancer risk assessment model based on a three-level sequential feature refining architecture, and outputting an integrated risk likelihood ratio; and finally generating a structured screening report containing hierarchical risk decision categories and clinical suggestions. According to the method, accurate, efficient and automatic early risk stratification of high-risk groups suffering from the pancreatic cancer with new diabetes mellitus is realized, and the early detection rate of the pancreatic cancer is remarkably improved.

The present invention relates to humanized anti-Lewis Y antibodies that specifically bind Lewis Y and do not show any cross-reactivity. In particular, the humanized anti-Lewis Y antibodies do not bind to Lewis b or any other blood group carbohydrate antigen. In particular, the present invention relates to humanized anti-Lewis Y antibodies for use in the treatment of cancer.

This invention relates to the field of biotechnology, and more particularly to a biomarker, kit, and application for the diagnosis of pancreatic malignant tumors. The biomarker comprises aldehyde-ketone reductase 1B10 protein and carbohydrate antigen 19-9 protein. This biomarker is a secreted serum protein that can specifically distinguish PDAC patients from normal individuals, and from individuals with benign pancreatic diseases, exhibiting high specificity without significant non-specific elevation interference. Combined detection with CA199 can synergistically enhance diagnostic efficacy, significantly reducing the rate of missed diagnoses and misdiagnoses. Simultaneously, this biomarker can assess the postoperative tumor resection effect in PDAC patients, predict whether curative resection is achieved, and provide an effective target for postoperative prognostic monitoring.

The present invention discloses novel monoclonal antibodies and functional fragments thereof that specifically bind to SLeA carbohydrate antigen with high specificity and selectivity. The invention further provides compositions comprising the antibodies or fragments thereof as well as uses of the antibodies, fragments and compositions.

The application provides a kit for detecting sialylated carbohydrate antigen KL-6 and a use method and application thereof, and relates to the field of in vitro detection. The kit for detecting sialylated carbohydrate antigen KL-6 provided by the application comprises magnetic beads, KL-6 antibodies, acridinium ester, a magnetic bead storage solution, an acridinium ester storage solution, a sample processing solution, a pre-priming solution and a priming solution. The sample processing solution comprises, in terms of mass fraction, 0.03-0.3% polyoxyethylene fatty acid ester, 0.3-2.0% bovine serum albumin, 0.3-2.0% raffinose, 0.3%-2.0% sodium hydroxide, 0.01-1.5% NaN3 and 0.3-1.5% sodium chloride, the rest is purified water, and the pH is 8-10. The kit can be used for determining sialylated carbohydrate antigen KL-6 in serum, and has high accuracy and strong anti-interference ability.

This invention belongs to the fields of immunology and molecular biology, specifically relating to a nanobody targeting the sialylated glycan antigen (KL-6) and its applications. The nanobody comprises any one of five sets of complementary determinant regions. This invention also provides a nucleic acid molecule encoding the nanobody, a carrier and host cell containing the nucleic acid molecule, a fusion protein and conjugate containing the nanobody, and a pharmaceutical composition containing the above substances. The nanobody of this invention exhibits high specificity and affinity, and can be used to prepare KL-6 detection reagents, in vivo imaging probes, or therapeutic products, particularly showing broad application prospects in the diagnosis and treatment of KL-6-related diseases such as interstitial lung disease.

The invention discloses a method and system for constructing an early diagnosis model of ovarian cancer based on multi-modal data, and relates to the technical field of methods for constructing the early diagnosis model of ovarian cancer, the method for constructing the early diagnosis model of ovarian cancer based on multi-modal data comprises the following steps: S1, obtaining a sample data set, the sample data set comprises pelvic MRI image data and serum samples; s2, extracting DCE-MRI quantitative parameters and ADC (Analog to Digital Converter) values from the pelvic MRI image data; s3, detecting the levels of human epididymal protein 4 and carbohydrate antigen 125 in the serum sample; s4, taking the DCE-MRI quantitative parameters, the ADC value, the serum human epididymal protein 4 level and the carbohydrate antigen 125 level as input characteristics, and constructing an ovarian cancer early diagnosis model; through pelvic MRI image data and serum sample data, an accurate and effective early diagnosis model of ovarian cancer is constructed, the sensitivity and specificity of early diagnosis of ovarian cancer are improved, and a reliable basis is provided for clinical diagnosis.

The present invention relates to the field of modified proteins, immunogenic compositions and vaccines comprising said modified proteins, their preparation and the use of such compositions in medicine. More specifically, the present invention relates to a modified Als 3 (Candida albicans lectin-like sequence 3) protein. The modified Als3 protein can be used as a carrier protein for other antigens, especially carbohydrate antigens or other antigens lacking T cell epitopes.

The application relates to the technical field of immunosensors, in particular to a Gd MOF composite material, an immunosensor and a preparation method and application thereof. The preparation method of the Gd MOF composite material comprises the following steps: dissolving polyether F127 in a mixed solvent, then adding gadolinium (Gd) salt and 5-aminoisophthalic acid (5-AIPA) to carry out a first heating reaction to obtain Gd MOF; dispersing the Gd MOF in a copper salt solution to carry out a second heating reaction to obtain the Gd MOF composite material. The application further provides a double-ligand Gd MOF composite material prepared by the method, a luminescent body combined with an antibody, an immunosensor and a preparation method. The application provides a novel MOF material, and the MOF material is used in an ECL sensing system, so that efficient detection of carbohydrate antigen 19-9 (CA19-9) is realized.

The application discloses an antibody against carbohydrate antigen 199 and application thereof, and relates to the field of antibodies. The antibody against carbohydrate antigen 199 disclosed by the application comprises a heavy chain complementarity determining region and a light chain complementarity determining region, the antibody provides an important raw material source for detection of carbohydrate antigen 199, and has good activity.

Disclosed herein is a glycoengineered tumor cell or a glycoengineered tumor cell fragment for use in treatment and / or prevention of cancer, in particular cancerous neoplasms, in a subject. The glycoengineered tumor cell or tumor cell fragment includes a tumor cell surface including one or more carbohydrate antigen moieties. Furthermore, a pharmaceutical composition including such a cell or cell fragment, a method for producing such a glycoengineered tumor cell or tumor cell fragment and a method of treatment of a subject including the administration of such a glycoengineered tumor cell or glycoengineered tumor cell fragment to a subject is disclosed.

The present invention relates to the field of modified proteins, immunogenic compositions and vaccines comprising said modified proteins, their preparation and the use of such compositions in medicine. More specifically, the present invention relates to a modified Sap2 (Secretory Aspartic Protease 2 of Candida albicans) protein. The modified Sap2 protein can be used as other antigens, in particular as a carrier protein for carbohydrate antigens or other antigens lacking T cell epitopes.